Drug Approval | February 20, 2026
Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
This transaction fundamentally strengthens Scinai's CDMO platform
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Subscribe To Our Newsletter & Stay Updated
